Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-four ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and twenty have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $337.91.

ALNY has been the topic of a number of research analyst reports. BMO Capital Markets boosted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Wall Street Zen lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Citigroup boosted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a research note on Thursday. Finally, JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a research note on Thursday, June 12th.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $322.83 on Friday. The business's 50-day moving average is $286.24 and its two-hundred day moving average is $263.33. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $326.03. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. The firm has a market capitalization of $42.09 billion, a PE ratio of -154.46 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same quarter last year, the firm earned ($0.16) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,899,281.72. This represents a 39.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALNY. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $27,000. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $28,000. Whipplewood Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.